Analysts Lift Targets to $2,000 While Options Traders Stay Cautious

MU closed June with its bull and bear camps further apart than ever. A wave of analyst upgrades pushed consensus price targets sharply higher. At the same time, options traders held their most defensive posture in 52 weeks.

---

The Analyst Surge

Ten firms raised price targets in the 48 hours after the June 24 earnings print. Cantor Fitzgerald's C.J. Muse moved to $2,000 from $1,500 on June 29. Barclays went to $2,000 from $1,175. DA Davidson matched that $2,000 level. Deutsche Bank moved to $1,550. Raymond James raised to $1,500.

The consensus mean sits at $1,454. With MU trading at $1,145, that implies roughly 27% upside to the average target — and 75% to the most bullish call.

EPS momentum underpins the enthusiasm. The 30-day EPS momentum factor ranks in the 95th percentile. The 90-day reading sits at the 80th percentile. Goldman Sachs remains the outlier, maintaining Neutral with a $1,100 target — the only major firm still below the current price.

---

Options Say: Not So Fast

The put/call ratio hit 1.398 on June 26 — a 52-week high. It has since eased to 1.375, but the 20-day average is 1.310 and the z-score sits at 1.94. That is the most sustained defensive options posture MU has seen all year.

This is not a new pattern. The prior stock report noted the PCR climbing into the June 24 print as a deliberate hedge rather than panic. The hedge paid off — the stock fell 13% the day after earnings before recovering. The PCR has not normalised. Options traders are not yet buying the $2,000 narrative.

---

Short Interest Rises, Borrow Stays Loose

Short interest climbed to 3.74% of free float as of June 29, up 11.8% over the past week and 12.3% over the past month. At 3.7%, this is a meaningful but not extreme short position for a large-cap semiconductor name.

Cost to borrow jumped 58% week-on-week to 0.35%. That is still very low in absolute terms. Availability remains exceptionally loose — well above any level that would constrain new short positions. The borrow market is not signalling a squeeze setup.

The short base appears to be a valuation hedge against the analyst enthusiasm, not a directional bet on business deterioration.

---

What to Watch

The next earnings date is September 30. Between now and then, the debate is between the $2,000 analyst targets and a PCR still sitting near its 52-week high. The stock is up 18% over the past month and down 5.5% over the past week — quarter-end flows and the ongoing DRAM price-fixing lawsuit remain active noise in the background.

• SI % FF: 3.74%, +11.8% week-on-week
• Cost to borrow: 0.35%, up 58% in one week
• PCR: 1.375, z-score 1.94, 52-week high 1.398
• Consensus price target mean: $1,454 (range: $1,100–$2,000)
• EPS momentum rank: 95th percentile (30-day)
• Next catalyst: Earnings September 30